Taro Pharmaceutical Industries (NYSE:TARO) Hits New 12-Month Low at $33.43

Taro Pharmaceutical Industries Ltd. (NYSE:TAROGet Rating) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $33.43 and last traded at $34.00, with a volume of 68 shares changing hands. The stock had previously closed at $34.22.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Taro Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 7th.

Taro Pharmaceutical Industries Trading Up 1.9 %

The company has a market cap of $1.34 billion, a price-to-earnings ratio of 14.69 and a beta of 0.66. The company’s 50 day moving average price is $36.90 and its 200 day moving average price is $40.97.

Taro Pharmaceutical Industries (NYSE:TAROGet Rating) last released its earnings results on Thursday, May 26th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.88 by ($0.15). Taro Pharmaceutical Industries had a return on equity of 5.45% and a net margin of 15.96%. The firm had revenue of $143.26 million during the quarter, compared to analyst estimates of $147.00 million. During the same quarter last year, the business posted $0.81 EPS. Sell-side analysts predict that Taro Pharmaceutical Industries Ltd. will post 3.86 earnings per share for the current year.

Institutional Trading of Taro Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Murchinson Ltd. increased its holdings in Taro Pharmaceutical Industries by 59.2% during the 4th quarter. Murchinson Ltd. now owns 159,203 shares of the company’s stock valued at $7,978,000 after acquiring an additional 59,203 shares in the last quarter. Eversept Partners LP increased its holdings in Taro Pharmaceutical Industries by 21.6% during the 1st quarter. Eversept Partners LP now owns 220,286 shares of the company’s stock valued at $9,530,000 after acquiring an additional 39,135 shares in the last quarter. Brandes Investment Partners LP increased its holdings in Taro Pharmaceutical Industries by 8.5% during the 1st quarter. Brandes Investment Partners LP now owns 379,322 shares of the company’s stock valued at $16,410,000 after acquiring an additional 29,606 shares in the last quarter. Krensavage Asset Management LLC increased its holdings in Taro Pharmaceutical Industries by 5.0% during the 1st quarter. Krensavage Asset Management LLC now owns 565,951 shares of the company’s stock valued at $24,483,000 after acquiring an additional 26,984 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Taro Pharmaceutical Industries by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 534,629 shares of the company’s stock valued at $23,128,000 after acquiring an additional 17,947 shares in the last quarter. Institutional investors and hedge funds own 12.28% of the company’s stock.

About Taro Pharmaceutical Industries

(Get Rating)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

Recommended Stories

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.